Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from a workshop. - Wikidata - awgldk - TriplyDB

Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from a workshop.

Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from a workshop.

http://www.wikidata.org/entity/Q37194359

about

Testing for heterogeneity among the components of a binary composite outcome in a clinical trial HIV Vaccine Trials Network: activities and achievements of the first decade and beyond.Robotic selection for the rapid development of stable CHO cell lines for HIV vaccine production

P2860

Q33596793-9B36C715-120E-496C-841B-E15EF33DAFE2 Q36464748-C4868CB2-6E53-4B44-BF52-52E7BB770ABE Q56995988-CA877876-3AF7-4975-A16A-3D973FE6B4EF

P2860

Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from a workshop.

http://www.wikidata.org/entity/Q37194359

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2007

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from a workshop.

@en

Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from a workshop.

@nl

type

label

Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from a workshop.

@en

Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from a workshop.

@nl

prefLabel

Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from a workshop.

@en

Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from a workshop.

@nl

P1433

Q37194359-026B80E2-8119-4308-826D-59C1A263BF06

P1476

Q37194359-0612709B-576D-42B7-88B6-AF287C302270

P2093

Q37194359-0DACA056-2B11-401E-8563-1C51BC2975A5

Q37194359-1AF3EBCC-5482-4256-AD09-014BAA486D44

Q37194359-2E42C18D-6180-4A2A-8D4A-E2E0AAA57D61

Q37194359-65EF3C17-A68B-407F-87DE-C0C11B57ACBD

Q37194359-8942A1A6-E3B6-4458-ADB5-FA199404C4A2

Q37194359-D2077876-D93B-49D4-809E-33C70CA1450D

Q37194359-DBEDE55E-FB74-4AA3-B9A9-4398631BEC0C

Q37194359-F8CFBAC3-066D-414D-ABD5-E6194B55B3B4

P2860

Q37194359-00DFD0BA-B6D2-4CEC-879E-FA4C2AD3F86B

Q37194359-09BEC802-B19B-4633-B428-A40EB66BFF69

Q37194359-2DBBCDA1-3081-41EA-AFAB-B605B4D510A4

Q37194359-4116695D-3E4E-4BAF-A26A-47056AC1B406

Q37194359-4B9F1C64-213A-4471-94EB-F46ACEBFC481

Q37194359-6B0FE753-A12F-42E9-9DAB-212363F2F3DA

Q37194359-6C5F129D-666B-4545-B0A6-5EFD8DC1BADB

Q37194359-6F4B14D3-410A-49ED-A945-31881817B62E

Q37194359-85A178AA-2EFD-4947-9AD6-7DFFD6C943DF

Q37194359-97CBDE09-178C-4B19-8BEB-367302B91BCC

P304

Q37194359-9C9727D4-D359-48DC-BF56-F2989347ED90

P31

Q37194359-32238443-9189-4C1A-AED2-146E56221CAC

P356

Q37194359-F03694DB-F9F6-4CCF-8567-B0C214B38E29

P407

Q37194359-5F69710A-1370-4310-A4AC-6D7D095D54C8

P433

Q37194359-AD057492-C8DD-48CE-84C1-70D15666226D

P478

Q37194359-578C6DEA-26DB-40BF-9145-9B972A7B1B20

P577

Q37194359-62BC9AEB-D77D-4131-8A92-91EE5FA9956F

P5875

Q37194359-7B13475A-E0FF-4FCB-996C-80D66F55CED5

P698

Q37194359-E68180FD-5DAD-47E0-868F-D50022EF994A

P921

Q37194359-9620CF0B-12CB-4604-B523-5146EF74ED13

P932

Q37194359-AD3FF336-DE51-4BCA-A41E-748A38D0E99B

P356

01.QAI.0000247227.22504.CE

P1433

Journal of Acquired Immune Deficiency Syndromes

P1476

Endpoints and regulatory issues in HIV vaccine clinical trials: lessons from a workshop.

@en

P2093

Ann Duerr

http://www.w3.org/2001/XMLSchema#string

Dean Follmann

http://www.w3.org/2001/XMLSchema#string

Massimo Cardinali

http://www.w3.org/2001/XMLSchema#string

Patricia Fast

http://www.w3.org/2001/XMLSchema#string

Peter Gilbert

http://www.w3.org/2001/XMLSchema#string

Stephen Tabet

http://www.w3.org/2001/XMLSchema#string

Steve Self

http://www.w3.org/2001/XMLSchema#string

Zoe Moodie

http://www.w3.org/2001/XMLSchema#string

P2860

HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries?

Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group

Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials.

The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs.

Design and interpretation of vaccine field studies.

Once-daily valacyclovir to reduce the risk of transmission of genital herpes.

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.

Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies

Design and analysis of stepped wedge cluster randomized trials.

Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys.

P304

49-60

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/01.QAI.0000247227.22504.CE

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

44

http://www.w3.org/2001/XMLSchema#string

P577

2007-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6721846

http://www.w3.org/2001/XMLSchema#string

P698

17075387

http://www.w3.org/2001/XMLSchema#string

P921

P932

2682948

http://www.w3.org/2001/XMLSchema#string